<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00807859</url>
  </required_header>
  <id_info>
    <org_study_id>20062042</org_study_id>
    <nct_id>NCT00807859</nct_id>
  </id_info>
  <brief_title>Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer</brief_title>
  <official_title>An Open-Label Study of AMG 386 in Combination With Either Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in Subjects With HER2-positive Locally Recurrent or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if AMG 386 in combination with either paclitaxel&#xD;
      and trastuzumab or capecitabine and lapatinib is safe and well tolerated in subjects with&#xD;
      HER2-positive locally recurrent or metastatic breast cancer.&#xD;
&#xD;
      This is an open-label phase 1b trial and has 2 study parts. Study part 1 is a dose escalation&#xD;
      study to determine a tolerable dose of AMG 386 in combination with paclitaxel and trastuzumab&#xD;
      (cohort A) or with capecitabine and lapatinib (cohort B). Study part 2 is cohort expansion of&#xD;
      the tolerable doses determined in part 1.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 9, 2009</start_date>
  <completion_date type="Actual">October 19, 2015</completion_date>
  <primary_completion_date type="Actual">February 27, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary objective is to identify the incidence of adverse events and clinical laboratory abnormalities defined as a dose limiting toxicity in subjects treated with AMG 386 plus paclitaxel and trastuzumab or with AMG 386 plus capecitabine and lapatinib</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence of adverse events and clinical laboratory abnormalities not defined as DLTs</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics (PK) of AMG 386, trastuzumab, and paclitaxel (cohort A) or AMG 386, lapatinib, and capecitabine (and its active metabolite, 5-FU; cohort B) when administered in combination</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the incidence of anti AMG 386 antibody formation</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the treatment effect as measured by the following: objective response rate (ORR), duration of response (DOR), change in tumor burden and progression-free survival (PFS)</measure>
    <time_frame>23 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Breast Tumors</condition>
  <condition>Cancer</condition>
  <condition>Locally Recurrent and Metastatic Breast Cancer</condition>
  <condition>Metastases</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Oncology</condition>
  <condition>Solid Tumors</condition>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386 30 mg/kg, Paclitaxel and Trastuzumab</intervention_name>
    <description>AMG 386 30 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W</description>
    <arm_group_label>Cohort A3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386 30 mg/kg, Capecitabine and Lapatinib</intervention_name>
    <description>AMG 386 30 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD</description>
    <arm_group_label>Cohort B3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386 10 mgkg, Paclitaxel and Trastuzumab</intervention_name>
    <description>AMG 386 10 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W</description>
    <arm_group_label>Cohort A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386 10 mg/kg, Capecitabine and Lapatinib</intervention_name>
    <description>AMG 386 10 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD</description>
    <arm_group_label>Cohort B1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically or cytologically confirmed adenocarcinoma of the breast with locally&#xD;
             recurrent or metastatic disease not amenable to any local treatment with curative&#xD;
             intent.&#xD;
&#xD;
          -  HER2-positive by FISH, CISH, or IHC 3+&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Left ventricular ejection fraction greater than or equal to institutional lower limit&#xD;
             of normal&#xD;
&#xD;
          -  Adequate laboratory studies (hematological, chemistries and urinalysis)&#xD;
&#xD;
          -  Life expectancy greater than or equal to 3 months&#xD;
&#xD;
          -  Cohort A only:&#xD;
&#xD;
          -  Trastuzumab naïve or trastuzumab in the neo-adjuvant setting&#xD;
&#xD;
          -  No clinically significant drop in cardiac function prior exposure to trastuzumab&#xD;
&#xD;
          -  No prior chemotherapy for metastatic or locally recurrent breast cancer&#xD;
&#xD;
          -  No prior lapatinib therapy&#xD;
&#xD;
          -  At least 3 weeks from enrollment since prior chemotherapeutic agents, including&#xD;
             taxanes, in the neoadjuvant or adjuvant setting&#xD;
&#xD;
          -  At least 3 months from enrollment since prior trastuzumab in the neoadjuvant or&#xD;
             adjuvant setting&#xD;
&#xD;
          -  Cohort B only:&#xD;
&#xD;
          -  Must have failed trastuzumab in the first-line metastatic setting. Trastuzumab must be&#xD;
             discontinued for at least 3 weeks prior to enrollment&#xD;
&#xD;
          -  Must have received prior chemotherapy as adjuvant therapy or for metastatic disease&#xD;
&#xD;
          -  Prior chemotherapy treatment must be discontinued for at least 3 weeks prior to&#xD;
             enrollment&#xD;
&#xD;
          -  No prior capecitabine&#xD;
&#xD;
          -  No prior lapatinib&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory breast cancer&#xD;
&#xD;
          -  Central nervous system metastasis&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Radiation therapy ≤ 14 days prior to enrollment.&#xD;
&#xD;
          -  Concurrent anticoagulation therapy, excluding aspirin, anti-platelet agents, low&#xD;
             molecular weight heparin or low dose warfarin per protocol.&#xD;
&#xD;
          -  Uncontrolled hypertension defined as diastolic blood pressure &gt; 90 mmHg OR systolic&#xD;
             blood pressure &gt; 140 mmHg.&#xD;
&#xD;
          -  Subjects with a history of prior malignancy, except:&#xD;
&#xD;
          -  For Cohort B only:&#xD;
&#xD;
          -  Current or prior history of long QT syndrome&#xD;
&#xD;
          -  Baseline ECG report of QTc interval of &gt; 480 milliseconds&#xD;
&#xD;
          -  Severe chronic liver disease (Child Pugh C)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New City</city>
        <state>New York</state>
        <zip>10956</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyack</city>
        <state>New York</state>
        <zip>10960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <zip>45042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caen Cedex 05</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Roche Sur Yon Cedex 9</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes Cedex 2</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pierre BÃ©nite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Kaufman PA, Wildiers H, Freyer G, Kemeny M, Gonçalves A, Jerusalem G, Stopeck A, Vrindavanam N, Dalenc F, Nanayakkara N, Wu B, Pickett CA. Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. Clin Breast Cancer. 2019 Feb;19(1):47-57. doi: 10.1016/j.clbc.2018.09.012. Epub 2018 Oct 9.</citation>
    <PMID>30420181</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 11, 2008</study_first_submitted>
  <study_first_submitted_qc>December 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2008</study_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMG 386</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Lapatinib</keyword>
  <keyword>HER2-positive</keyword>
  <keyword>metastatic breast cancer</keyword>
  <keyword>locally recurrent breast cancer</keyword>
  <keyword>Taxol</keyword>
  <keyword>Herceptin</keyword>
  <keyword>Xeloda</keyword>
  <keyword>Tykerb</keyword>
  <keyword>anti-angiogenic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Trebananib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

